Tara L. Lin - Concepedia

Author

Tara L. Lin

University of Kansas Medical Center ORCID

Also Known As

Chua, SE, F De, Jimnez, Leong, Man Chong, T L Lin, T Lin, T. L. Lin, T. Lin, T.L. Lin, Tara L. Lin, Tara L Lin

377

Publications

7.1K

Citations

H-Index

Concepts

All Affiliations

University of Kansas Medical Center University of Kansas University of California, Los Angeles Oregon Health & Science University The Ohio State University

About

Tara L. Lin is an author at University of Kansas Medical Center specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	28	3.6K
2	Health Sciences	12	12	1.6K
3	Biomedical Engineering	2	2	132
4	Public Health	1	1	21
5	Biostatistics	1	1	181

Tara L. Lin

Publications

6.1K

Citations

H-Index

Page 1

	Year	Citations
Functional genomic landscape of acute myeloid leukaemia Jeffrey Tyner, Cristina E. Tognon, Daniel Bottomly, Nature Hematological MalignancyChromatinFunctional GenomicsMixed-phenotype Acute LeukemiaGenetics	2018	1.4K
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes, Journal of Clinical Oncology Mixed-phenotype Acute LeukemiaPharmacotherapyMetronomic ChemotherapyMyeloid NeoplasiaHematological Malignancy	2018	958
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study Andrew H. Wei, Stephen A. Strickland, Jing-Zhou Hou, Journal of Clinical Oncology	2019	680
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia Daniel Bottomly, Nicola Long, Anna Reister Schultz, Cancer Cell	2022	336
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell, The Lancet Haematology Hematological MalignancyOncologyCpx-351 Versus 7+3Mixed-phenotype Acute LeukemiaHematology	2021	200
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial Amy Burd, Ross L. Levine, Amy S. Ruppert, Nature Medicine Hematological MalignancyProspective Genomic ProfilingOncologyMedicineAcute Myeloid Leukemia	2020	181
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults Mark R. Litzow, Zhuoxin Sun, Ryan J. Mattison, New England Journal of Medicine	2024	171
Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes, Journal of Clinical Oncology Secondary AmlPrognosisPharmacotherapyLogistic AnalysisAntecedent Mds	2016	164
Hedgehog pathway as a drug target: Smoothened inhibitors in development Tara L. Lin, William Matsui OncoTargets and Therapy	2012	142
Overcoming Wnt–β-catenin dependent anticancer therapy resistance in leukaemia stem cells John M. Perry, Tao Fang, Anuradha Roy, Nature Cell Biology Hematological MalignancyCell TherapyOncologyMedicineCancer Cell Biology	2020	129

Page 1